FlowVax BreastCA
Triple-Negative Breast Cancer
Pre-clinicalActive
Key Facts
About Flow Pharma
Flow Pharma is a private, pre-clinical stage biotech focused on immunotherapy using its proprietary FlowVax platform. The platform utilizes AI-designed synthetic peptides encapsulated in precisely constructed microspheres to stimulate targeted cytotoxic T-lymphocyte (CTL) responses. Its lead programs target COVID-19 (FLOVID-20) and treatment-resistant cancers like triple-negative breast cancer, with all assets currently in pre-clinical or research stages pending FDA approval. The company emphasizes a scalable, room-temperature stable dry powder format suitable for inhalation or injection.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| RejuverSen Antibody | Centenara Labs | Pre-Clinical |
| Undisclosed circRNA Program | CircNova | Pre-clinical |
| Radiolabeled hTAB004 (Therapeutic) | OncoTAb | Preclinical |
| AI Predictor for TNBC | PathomIQ | Development/Validation |
| TNBC Biomarker/Target Discovery | CogNano | Preclinical (Mouse Studies) |